AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

MRA Launches “Fight Back Give Back” Campaign to Highlight Importance of Clinical Trials in Patient Care and Research Process

February 25, 2019

WASHINGTON, DC--(BUSINESS WIRE)--Feb 25, 2019--The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today launches its nationwide “Fight Back Give Back” campaign to highlight the importance of clinical trials in driving progress towards curing disease.

“Too many patients never consider participating in clinical trials or else too often wait until they have few if any other options,” said MRA President and CEO Michael Kaplan. “However, for many patients, clinical trials represent the best way to get access to new, potentially better treatments. We believe that until you’ve considered clinical trials, you haven’t considered all of your options.”

Jamie Troil Goldfarb, a stage IV melanoma survivor, credits enrolling in a clinical trial at the National Cancer Institute with saving her life. “I would not be alive today, I mean hands down, without clinical trials. Stage IV melanoma had a 14% five-year survival rate when I was diagnosed in 2012,” she states.

The campaign will address one of the biggest problems facing our medical research process: too many clinical trials and not enough patient volunteers to effectively develop new, potentially game-changing therapies to better treat and eventually cure cancer.

The MRA campaign focuses on three areas designed to increase awareness of the critical roll of clinical trials among patients, families, and doctors:

Every FDA-approved drug that exists today was made possible because of clinical trials. Clinical trials are an important treatment option for all patients, yet only one out of every 20 cancer patients enroll in a clinical trial. 1 This is despite high rates of satisfaction among patient volunteers, in fact 94% of clinical trial participants with cancer would participate in another trial if it were offered. 2

Learn more about the campaign at CureMelanoma.org/FightBack

About Melanoma Research Alliance (MRA)

Founded in 2007 under the auspices of the Milken Institute, with the generous support of Debra and Leon Black, the Melanoma Research Alliance exists to accelerate treatment options and find a cure for melanoma. As the largest nonprofit funder of melanoma research, it has dedicated over $101 million and leveraged an additional $101 million towards its mission. Through its support, MRA has championed revolutions in immunotherapy, targeted therapies, novel combinations and diagnostics. Due to the ongoing support of its founders, 100 percent of donations to MRA go directly to its melanoma research program. MRA’s ability to fund wide-ranging research in melanoma is amplified by unique collaborations and partnerships with individuals, private foundations, and corporations. Visit http://www.CureMelanoma.org for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190225005290/en/

CONTACT: For Immediate Release

Cody R. Barnett, Director of Communications

M: (717) 880-7100

E-mail:cbarnett@curemelanoma.org

KEYWORD: UNITED STATES NORTH AMERICA DISTRICT OF COLUMBIA

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY PHILANTHROPY RESEARCH OTHER PHILANTHROPY SCIENCE FOUNDATION FUND RAISING GENERAL HEALTH

SOURCE: Melanoma Research Alliance

Copyright Business Wire 2019.

PUB: 02/25/2019 09:30 AM/DISC: 02/25/2019 09:30 AM

http://www.businesswire.com/news/home/20190225005290/en